Custom Antibody Market

The global custom antibody market is projected to reach USD 1.13 billion by 2031, up from USD 0.72 billion in 2026, at a CAGR of 9.5% from 2026 to 2031. Market growth is driven by research organizations increasingly outsourcing antibody development and growing demand for highly specific antibodies in proteomics, biomarker discovery, and precision medicine.

The global custom antibody market is moderately fragmented. Leading players include GenScript (US), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), among others. Companies in this market are adopting strategies such as expanding service portfolios, developing recombinant antibody platforms, forming partnerships, making acquisitions, and expanding geographically to strengthen their competitive positions. For example, major players are increasingly investing in custom monoclonal and recombinant antibody development, high-throughput screening, antibody engineering, purification, characterization, and labeling services to address growing demand from pharmaceutical, biotechnology, diagnostic, CRO, and academic customers.

To know about the assumptions considered for the study download the pdf brochure

GenScript (US)

GenScript is a leading participant in the custom antibody market, offering a broad portfolio of services that includes custom monoclonal and polyclonal antibody development, recombinant antibody generation, antibody sequencing, engineering, purification, labeling, and validation. The company supports pharmaceutical, biotechnology, diagnostic, and academic customers across research and therapeutic development workflows. Its integrated capabilities spanning antigen design, immunization, hybridoma development, recombinant expression, and large-scale production strengthen its position as an end-to-end custom antibody service provider. GenScript also continues to expand advanced antibody discovery capabilities through high-throughput screening, recombinant technologies, and application-specific customization.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a major player in the custom antibody market, providing comprehensive antibody development and production services through its life sciences portfolio. Its capabilities include antigen design and production, polyclonal and monoclonal antibody generation, hybridoma development, recombinant antibody production, purification, conjugation, and assay-specific validation. The company serves pharmaceutical and biotechnology companies, research institutes, diagnostic developers, and CROs. Thermo Fisher’s broad technology base, global laboratory infrastructure, and ability to integrate antibody services with protein expression, analytical characterization, and downstream research tools support its strong competitive position in the market.

Bio-Rad Laboratories, Inc. (US)

Bio-Rad Laboratories participates in the custom antibody market through specialized recombinant antibody generation, engineering, production, and long-term supply services. The company has established relationships with pharmaceutical, biotechnology, and diagnostic organizations requiring highly specific antibodies for research, assay development, and diagnostic applications. Its recombinant antibody capabilities support improved reproducibility, defined sequence control, and consistent long-term supply compared with conventional antibody production approaches. Bio-Rad also offers antibody characterization and application support, helping customers develop reagents suited to specific research and diagnostic workflows.

Agilent Technologies, Inc. (US)

Agilent Technologies participates in the custom antibody market primarily through antibody development and advanced immunohistochemistry and pathology-related capabilities, particularly following the integration of Dako technologies. The company supports antibody development and validation for biomarker research, tissue-based assays, companion diagnostics, and translational research. Agilent’s strength lies in combining antibody reagents with staining platforms, pathology workflows, and expertise in diagnostic assay development. This integrated approach allows the company to support pharmaceutical and biotechnology customers seeking highly specific antibodies for oncology biomarker development, precision medicine, and diagnostic applications.

Merck KGaA (Germany)

Merck KGaA has a presence in the custom antibody market through its life science business, offering antibody development, recombinant protein and antibody production, purification, conjugation, and analytical support capabilities. The company serves pharmaceutical and biotechnology companies, academic laboratories, and diagnostic developers requiring customized reagents for research and biologics development. Merck’s broader expertise in bioprocessing, protein sciences, analytical technologies, and life science research enables it to support multiple stages of antibody development. Its global reach and extensive life science infrastructure further strengthen its ability to serve customers across major research markets.

Market Ranking

The custom antibody market is moderately fragmented, with competition driven by service portfolios, recombinant antibody technologies, engineering capabilities, and end-to-end development services. Key differentiators include antibody generation, purification, characterization, validation, and the ability to serve pharmaceutical, biotechnology, diagnostic, CRO, and academic customers.

GenScript (US) offers end-to-end custom antibody services, including antigen design, monoclonal and polyclonal antibody development, recombinant production, engineering, purification, and validation. Its integrated services and scalable capabilities support research, diagnostics, and therapeutic discovery. Thermo Fisher Scientific Inc. (US) provides custom antibody development and production, including hybridoma development, recombinant expression, purification, conjugation, and validation. Its global infrastructure and broad life sciences portfolio strengthen its competitive position.

Bio-Rad Laboratories, Inc. (US) focuses on custom recombinant antibody generation, engineering, and production. Its capabilities support antibody specificity, batch consistency, and reliable supply for research and diagnostic applications. Agilent Technologies, Inc. (US) supports antibody-related applications in immunohistochemistry, pathology, and biomarker research. Its expertise in tissue-based assays and diagnostic workflows supports translational research and precision oncology.

Merck KGaA (Germany) supports custom antibody workflows through antibody development, recombinant expression, purification, and analytical services. Its broader life sciences capabilities and global customer network strengthen its market presence.

Related Reports:

Custom Antibody Market by Service (Development, Purification, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutic), Indication (Oncology, Immunology, Infectious, CVD), Competition, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]